Back to Peptide Deep Dives
Peptide Deep Dives•••11 min read

What Is GHRP-6?

What GHRP-6 is, what human studies actually tested, why FDA lists it as a safety risk, how it differs from approved secretagogues, and its 2026 status.

PeptIQ Team
Peptide Research & Education
GHRP-6: Evidence, Side Effects & 2026 FDA Status

PeptIQ app

Track your peptide protocols in PeptIQ

Log injections, vial supply, and reminders. Use peptiq.io calculators when you need math on the web.

Get the appOpen web app

iOS, Android, and web

Ask PeptIQ

Two taps on our guided quiz, then keep going in iMessage with sources — not Instagram screenshots.

Start the quizOr try Peptide X Quiz →

TL;DR

GHRP-6 is the first growth hormone-releasing peptide: a six-amino-acid synthetic peptide, described in 1984, that makes the pituitary release a burst of growth hormone. It is sold online as a research chemical for muscle, recovery and "natural GH" goals.

  • It works on the ghrelin receptor, and it was found before that receptor was. Researchers built GHRP-6 a decade before the receptor it hits was cloned in 1996, and fifteen years before the natural hormone that normally activates that receptor, ghrelin, was identified in 1999.
  • The growth hormone response in humans is real and well documented. In a 1990 study in normal men, GHRP-6 raised growth hormone on its own and acted synergistically with growth hormone-releasing hormone. That reliability is why endocrine units adopted it as a diagnostic provocative test, not as a treatment.
  • The same study found it is not selective. Serum prolactin and cortisol also rose at the highest exposure tested.
  • There is no human trial of GHRP-6 for muscle, fat loss, recovery or healing. Searching ClinicalTrials.gov on November 18, 2026 returns no registered study of GHRP-6 for any indication. Its cytoprotection research program is still in pigs and dogs.
  • The best outcome data in this drug class is discouraging. An oral ghrelin mimetic raised growth hormone into the young-adult range for two years and increased fat-free mass, but did not reduce visceral fat, raised fasting blood glucose and lowered insulin sensitivity. A 563-patient Alzheimer's trial of the same compound found no clinical benefit, and a hip-fracture trial was stopped early over a heart-failure signal.
  • Status in 2026: no FDA-approved GHRP-6 product, placed by FDA on its significant safety risks list for outsourcing facilities, sitting in Category 3 of the 503A nominated-substances list, absent from the October 2026 HHS peptide compounding policy, and prohibited in sport at all times.

This PeptIQ.io guide was written on November 18, 2026 from PubMed, ClinicalTrials.gov, FDA compounding and import records, Drugs@FDA and the WADA Prohibited List. It contains no dosing information.

Talk to a licensed clinician before using anything sold as GHRP-6.

What Is GHRP-6?

In 1984, Cyril Bowers and colleagues reported a new synthetic hexapeptide that acted directly on the pituitary to release growth hormone "without a concomitant release of LH, FSH, TSH, or PRL." That peptide, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2, became known as growth hormone-releasing peptide-6. It was active across rats, monkeys, lambs and calves, and the authors noted it had "the attributes of a hypophysiotropic hormone" — a signal the body ought to have a receptor for.

They were right, but it took twelve more years to find it. In 1996 a Merck team cloned a G protein-coupled receptor in the pituitary and hypothalamus and showed it was the target of this class of compounds, which they called growth hormone secretagogues. Their paper explicitly noted that the finding "supports the notion that the GHSs mimic an undiscovered hormone."

PeptIQ.io / GHRP-6 / 01

A drug that found its hormone backwards.

GHRP-6 is not growth hormone and not growth hormone-releasing hormone. It is a synthetic key cut for the ghrelin receptor, discovered before anyone knew that lock existed.

  1. 1984

    The peptide came first

    A six-amino-acid synthetic peptide was shown to act directly on the pituitary to release growth hormone. Its authors said it behaved like a hormone the body must have a receptor for.

  2. 1996

    Then the receptor

    A receptor in the pituitary and hypothalamus was cloned and identified as the target of this class. Its natural signal was still unknown.

  3. 1999

    Then the actual hormone

    Ghrelin, a hunger signal made in the stomach, turned out to be that natural ligand. GHRP-6 had been imitating a gut hormone for fifteen years.

What that receptor sets off

  • Growth hormone

    A short pulse: up within minutes, usually back to baseline inside two hours.

  • Prolactin + cortisol

    Both roughly doubled at the highest exposure studied in normal men.

  • Appetite

    Agonizing a hunger receptor increases hunger. The trait that defines GHRP-6 in practice.

The 1984 paper called it specific. The 1990 human study found the spillover.

Evidence, not marketing.Nov 2026
Sources: Bowers et al., Endocrinology 1984 (PubMed 6714155); Bowers et al., J Clin Endocrinol Metab 1990 (PubMed 2108187); Howard et al., Science 1996 (PubMed 8688086); Kojima et al., Nature 1999 (PubMed 10604470). Simplified for education; not treatment advice.

That hormone turned up in 1999, and not where anyone expected: ghrelin, a 28-amino-acid peptide purified from rat stomach. So the honest description of GHRP-6 is backwards from how it is usually marketed. It is not a growth hormone. It is not growth hormone-releasing hormone either. It is a small synthetic molecule that happens to fit the receptor for a gut hormone that signals hunger, and growth hormone release is one of several things that receptor does.

How it differs from the other peptides in this family

Three different mechanisms get grouped together as "GH peptides," and the distinction matters when reading claims:

FamilyExamplesWhere it acts
GHRH analoguessermorelin, tesamorelin, CJC-1295The growth hormone-releasing hormone receptor
GH-releasing peptides (GHRPs)GHRP-6, GHRP-2 (pralmorelin), hexarelinThe ghrelin receptor, GHS-R1a
Non-peptide secretagoguesibutamoren (MK-677), macimorelinThe same ghrelin receptor, orally active

Because GHRPs and GHRH analogues work through separate pathways, giving both produces a larger growth hormone pulse than either alone. That synergy is a documented pharmacology finding from the 1990 human study, and it is the entire basis of the stack marketing you see online. It describes a hormone spike. It does not describe an outcome.

What Happens in the Body

The published human pharmacology is narrow but consistent.

Growth hormone rises, quickly and briefly. Across early human work, growth hormone climbed within minutes of an intravenous injection, peaked inside the first half hour, and was usually back to baseline within two hours.

Other pituitary hormones rise too. In the 1990 study in 18 normal men, serum prolactin and cortisol roughly doubled above baseline at the highest exposure studied, while luteinizing hormone and thyroid-stimulating hormone did not change in the first hour. Later work put the same point less gently: FDA's own compounding risk notice flags "potential effect on cortisol" as a GHRP-6 safety concern. A cortisol bump is the opposite of what most people buying it for recovery believe they are getting.

It makes people hungry. This is the predictable consequence of agonizing a hunger-hormone receptor, and it is the trait that separates GHRP-6 from the rest of its family in practice.

Published human exposure data comes from a single small study. A 2013 pharmacokinetic study in nine male healthy volunteers in Havana described a two-compartment profile with a distribution half-life of roughly eight minutes and an elimination half-life around two and a half hours. Four of the nine had unexplained concentration spikes during elimination. That is the extent of the human exposure literature: nine men, one site, single injections.

What the Human Evidence Actually Shows

PeptIQ.io / GHRP-6 / 02

Strong pharmacology, missing outcomes.

The hormone spike is the best-documented thing about GHRP-6. Everything people buy it for is on the rung with no studies.

  1. Hormone response in humans

    Growth hormone rises reliably, and rises further when combined with a growth hormone-releasing hormone analogue. Documented since 1990.

    Established
  2. Use as a diagnostic test

    Paired with a releasing-hormone analogue, it became a provocative test with defined cut-offs for confirming adult growth hormone deficiency. One supervised use, to measure — not to treat.

    Established
  3. Human exposure data

    One published pharmacokinetic study: nine healthy men, single injections, one site. Four of the nine had unexplained concentration spikes.

    Thin
  4. Animal tissue protection

    Reduced infarct size in a pig model, protection in an organ-failure model, nerve-injury work in rodents, and a 28-day dog safety study in 2025. Still preclinical after two decades.

    Animals only
  5. Muscle, fat loss or recovery in people

    No registered trial of GHRP-6 for any indication on ClinicalTrials.gov as of Nov 18, 2026. The marketing claims sit entirely on this empty rung.

    Untested
Evidence, not marketing.Nov 2026
Sources: Bowers et al., J Clin Endocrinol Metab 1990 (PubMed 2108187); Corneli et al., Pituitary 2007 (PubMed 17429591); Cabrales et al., Eur J Pharm Sci 2013 (PubMed 23099431); Berlanga et al., Clin Sci 2007 (PubMed 16989643); Cibrián et al., Clin Sci 2006 (PubMed 16417467); Castro et al., Regul Toxicol Pharmacol 2025 (PubMed 40024561); ClinicalTrials.gov search, Nov 18, 2026.

Established human use: diagnosis, not therapy. The one role GHRP-6 genuinely earned in medicine is as a provocative test agent. Adult growth hormone deficiency has to be proven biochemically, and a 2007 review of diagnostic testing lists growth hormone-releasing hormone combined with a secretagogue such as GHRP-6 among the maximal tests that have "well-defined cut-off limits, are reproducible, are independent of age and gender, and are able to distinguish between normal and GHD subjects." Note what the test is for: confirming a deficiency in people with pituitary disease. It is a measuring instrument, used once, under supervision.

No registered trials. ClinicalTrials.gov, checked November 18, 2026, has no registered study of GHRP-6. A keyword search for "GHRP" returns three records, and they are other compounds: a terminated phase 2 study of a GHRP-1 depot in dialysis patients that closed after enrolling three people, a withdrawn GHRP-3 infusion study, and an observational study in aging men.

The cytoprotection program never reached people. The most interesting GHRP-6 research is not about muscle at all. A Cuban biotech group pursued it as a tissue-protection drug, reporting reduced infarct size in a pig model of coronary occlusion in 2007, protection in a model of multiple organ failure in 2006, and nerve-injury work in rodents. The program has a development code, CIGB-500, and the most recent indexed publication is a 2025 28-day safety study in beagle dogs. After almost twenty years, this line of work has produced no indexed human efficacy trial. Animal cardioprotection is a reason to run a trial, not a reason to inject a vial.

The class data that does exist is a warning. Because GHRP-6 itself was never developed commercially, the most informative human evidence comes from ibutamoren (MK-677), an orally active compound acting on the same receptor, which Merck took into large randomized trials:

  • A two-year, double-blind, placebo-controlled trial in 65 healthy adults aged 60 to 81 raised growth hormone and IGF-1 to young-adult levels. Fat-free mass increased by about 1.1 kg versus a small loss on placebo. But abdominal visceral fat and total fat mass did not differ, limb fat increased more than on placebo, body weight rose, fasting blood glucose rose, insulin sensitivity decreased, and cortisol rose. Appetite increase, transient lower-leg swelling and muscle pain were the common side effects.
  • A 563-patient, 12-month randomized trial in mild-to-moderate Alzheimer's disease found no clinical effect on progression, despite confirmed target engagement.
  • A randomized phase 2b trial in 123 elderly hip-fracture patients was terminated early over a potential safety signal of congestive heart failure, and most functional performance measures did not improve even though IGF-1 clearly did. FDA cites that trial by name in its compounding risk notice for ibutamoren.

So in this receptor family, the hormone response is the easy part. Two decades of randomized trials found that raising growth hormone and IGF-1 did not reliably deliver function, visceral fat loss, cognition or recovery, and in one frail population the attempt had to be stopped.

Regulatory Status in 2026

PeptIQ.io / GHRP-6 / 03

The class was tested. This is what came back.

GHRP-6 itself was never developed commercially, so the useful human evidence comes from an orally active compound acting on the same ghrelin receptor — tested in large randomized trials.

  • 2 years, 65 older adults

    Growth hormone and IGF-1 reached young-adult levels. Fat-free mass rose about 1.1 kg. Visceral and total fat did not change, fasting glucose rose and insulin sensitivity fell.

  • 563 patients, 12 months

    A randomized Alzheimer's disease trial found no clinical effect on progression, even with confirmed target engagement.

  • 123 hip-fracture patients

    Phase 2b terminated early over a potential congestive heart failure signal. IGF-1 rose; most functional measures did not improve.

What FDA says about GHRP-6

Cortisol. Blood sugar. Impurities.

FDA lists GHRP-6 as a bulk substance that may present significant safety risks, citing immunogenicity from aggregation and peptide-related impurities, a potential effect on cortisol, and higher blood glucose through reduced insulin sensitivity.

Raising a hormone is not the same as improving an outcome.

Evidence, not marketing.Nov 2026
Sources: Nass et al., Ann Intern Med 2008 (PubMed 18981485); Sevigny et al., Neurology 2008 (PubMed 19015485); Adunsky et al., Arch Gerontol Geriatr 2011 (PubMed 21067829); FDA bulk substances significant safety risks list, GHRP-6 entry added September 29, 2023, read Nov 18, 2026.

No approved product anywhere in Drugs@FDA. There is no FDA-approved drug whose active ingredient is GHRP-6, for any route or indication. The only growth hormone secretagogue ever approved in the United States is macimorelin (Macrilen, NDA 205598, approved December 20, 2017) — an oral agent approved for diagnosing adult growth hormone deficiency, not for treating anything, and Drugs@FDA now lists its product as discontinued.

On FDA's significant safety risks list. FDA placed "Growth hormone releasing peptide-6 (GHRP-6)" on its list of bulk drug substances that may present significant safety risks for 503B outsourcing facilities on September 29, 2023. FDA's stated reasoning is worth reading verbatim: compounded GHRP-6 drugs "may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation and peptide-related impurities," and the agency "has identified limited safety-related information, but the available data reveal safety concerns including potential effect on cortisol and increase in blood glucose due to decreases in insulin sensitivity."

Category 3 for 503A pharmacies. On FDA's list of bulk drug substances nominated for use in compounding under section 503A, updated May 14, 2026, GHRP-6 appears in Category 3: nominated without adequate support — meaning nobody submitted enough information for FDA to evaluate it. GHRP-2 is in the same category.

Not in the October 2026 HHS policy. The enforcement-discretion policy published in the Federal Register on October 30, 2026 covers a short list of peptides in its Appendix A. GHRP-6 is not one of them. Our guide to that policy explains what it does and does not permit, and the general FDA compounded peptides guide covers the category system.

Flagged at the border. FDA's Import Alert 66-41, which allows detention without physical examination of unapproved new drugs, includes a listing for "GHRP6 (Growth Hormone Releasing Peptide)" from a Chinese supplier.

Banned in sport at all times. The WADA 2026 Prohibited List names GHRP-6 by name under section S2.2.4, growth hormone releasing factors, alongside hexarelin, GHRP-1 through GHRP-5 and GHRP-2. Section S2 substances are prohibited in and out of competition, so an off-season cycle is not a loophole.

Taken together: a peptide with real pharmacology, a legitimate niche as a diagnostic reagent, no approval, no registered trials, an explicit FDA safety notice, and a permanent anti-doping ban.

Safety Questions to Raise With a Clinician

These are the questions the published record says are worth asking. None of them have a dosing answer.

  • What does this do to my cortisol? Published human data show cortisol rising with this peptide, and FDA names cortisol as a safety concern. If you are tracking recovery, sleep or mood, that matters.
  • What does it do to my blood sugar? FDA cites increased blood glucose through reduced insulin sensitivity. The two-year trial of an oral compound in this class measured exactly that. If you have prediabetes, insulin resistance or are on a GLP-1, this is a direct interaction question.
  • What about prolactin? It rose in the original human study. Prolactin elevation has real clinical consequences worth checking rather than assuming.
  • What is my IGF-1 doing, and is that something I want raised? Our IGF-1 LR3 guide covers the cancer-epidemiology context for sustained IGF-1 elevation.
  • How does appetite stimulation fit my actual goal? A ghrelin-receptor agonist increases hunger. For a cachexia patient that is the point; for someone trying to lose fat it works against the plan.
  • Is my heart healthy? The one randomized trial in frail patients in this class stopped over a heart-failure signal.
  • What is actually in the vial? A substance with no approved product has no regulated manufacturer, and FDA's own concern is aggregation and peptide-related impurities. Our certificate of analysis guide explains what a lab report can and cannot prove.

For background on this family of compounds, the GHRP-6 brand site in the Meds.you portfolio describes it as not FDA approved and not currently available, with a physician-supervised model in development — which is a more accurate framing of availability than most pages selling vials today.

How PeptIQ.io Helps

PeptIQ.io does not sell peptides. Our Peptide Claim Auditor takes a link to an Instagram, TikTok, X or Reddit post and checks its claims against published research — useful for the "GHRP-6 is natural GH" genre of post, where the pharmacology is real but the outcome claim has no trial behind it. The GHRP-6 compound profile tracks its regulatory status, and our guide to vetting a peptide source covers supply-chain questions. If you and your clinician agree on a plan, the PeptIQ app keeps medications, labs and symptoms on one timeline, and PeptIQ AI answers questions against your own log instead of a forum thread.

Talk to a Licensed Clinician

Talk to a licensed clinician before using anything sold as GHRP-6. It is an unapproved drug with no efficacy trials, an FDA safety notice naming cortisol and blood sugar effects, a documented impurity and immunogenicity concern, and a permanent ban in tested sport. If you are already using it, tell your clinician — fasting glucose, A1c, IGF-1, prolactin and cortisol are all measurable, and a baseline is more useful than a guess.

Frequently Asked Questions

Q: What is GHRP-6?

A: GHRP-6 is a synthetic six-amino-acid peptide first described in 1984 that stimulates the pituitary to release a burst of growth hormone. It acts on the ghrelin receptor, GHS-R1a, which was not identified until 1996, and its natural hormone, ghrelin, was not discovered until 1999.

Q: Does GHRP-6 build muscle?

A: No human trial has tested GHRP-6 for muscle growth, body composition or recovery. The closest evidence is from ibutamoren, an oral compound acting on the same receptor: a two-year randomized trial in healthy older adults increased fat-free mass by about a kilogram, but did not reduce visceral or total fat and reduced insulin sensitivity. Separate randomized trials of that compound found no benefit in Alzheimer's disease and were stopped early in hip-fracture patients over a heart-failure signal.

Q: Is GHRP-6 FDA approved?

A: No. There is no FDA-approved GHRP-6 product for any use. FDA placed GHRP-6 on its list of bulk substances that may present significant safety risks for outsourcing facilities in September 2023, and it sits in Category 3 of the 503A nominated-substances list, meaning it was nominated without adequate supporting information. The only approved growth hormone secretagogue in the United States, macimorelin, was approved as a diagnostic test.

Q: What are the side effects of GHRP-6?

A: The documented human effects beyond growth hormone release are increased prolactin and cortisol, strong appetite stimulation through the ghrelin receptor, and — per FDA's compounding notice — increased blood glucose from reduced insulin sensitivity. FDA also flags immunogenicity risk from peptide aggregation and impurities in compounded product.

Q: What is the difference between GHRP-6 and GHRP-2 or ipamorelin?

A: All three act on the ghrelin receptor rather than the growth hormone-releasing hormone receptor. GHRP-6 is the original and is the most appetite-stimulating of the group. GHRP-2 (pralmorelin) is more potent for growth hormone release; FDA lists it alongside GHRP-6 as a safety-risk substance for compounding. Ipamorelin is more selective. None of them has a trial showing improved clinical outcomes, and none is FDA approved.

Q: Is GHRP-6 banned in sport?

A: Yes. The WADA 2026 Prohibited List names GHRP-6 explicitly under section S2.2.4 as a growth hormone-releasing peptide. S2 substances are prohibited at all times, both in and out of competition.

Related Guides

Sources

  • Bowers CY, Momany FA, Reynolds GA, Hong A. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology. 1984;114(5):1537-1545. PubMed 6714155
  • Bowers CY, Reynolds GA, Durham D, et al. Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. J Clin Endocrinol Metab. 1990;70(4):975-982. PubMed 2108187
  • Howard AD, Feighner SD, Cully DF, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996;273(5277):974-977. PubMed 8688086
  • Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402(6762):656-660. PubMed 10604470
  • Cabrales A, Gil J, Fernández E, et al. Pharmacokinetic study of growth hormone-releasing peptide 6 (GHRP-6) in nine male healthy volunteers. Eur J Pharm Sci. 2013;48(1-2):40-46. PubMed 23099431
  • Corneli G, Gasco V, Prodam F, et al. Growth hormone levels in the diagnosis of growth hormone deficiency in adulthood. Pituitary. 2007;10(2):141-149. PubMed 17429591
  • Berlanga J, Cibrian D, Guevara L, et al. Growth-hormone-releasing peptide 6 (GHRP6) prevents oxidant cytotoxicity and reduces myocardial necrosis in a model of acute myocardial infarction. Clin Sci (Lond). 2007;112(4):241-250. PubMed 16989643
  • Cibrián D, Ajamieh H, Berlanga J, et al. Use of growth-hormone-releasing peptide-6 (GHRP-6) for the prevention of multiple organ failure. Clin Sci (Lond). 2006;110(5):563-573. PubMed 16417467
  • Castro J, et al. Subchronic safety assessment of CIGB-500 in beagle dog after repeated daily dose administration over 28 days. Regul Toxicol Pharmacol. 2025. PubMed 40024561
  • Nass R, Pezzoli SS, Oliveri MC, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med. 2008;149(9):601-611. PubMed 18981485
  • Sevigny JJ, Ryan JM, van Dyck CH, et al. Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial. Neurology. 2008;71(21):1702-1708. PubMed 19015485
  • Adunsky A, Chandler J, Heyden N, et al. MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study. Arch Gerontol Geriatr. 2011;53(2):183-189. PubMed 21067829
  • Vasylieva V, West A, Karpman E. Peptides in urology and sexual medicine: clinical effectiveness, indications, and safety: a narrative review. Sex Med Rev. 2026;14(4):qeag078. PubMed 42862021
  • FDA. Certain bulk drug substances for use in compounding that may present significant safety risks, GHRP-6 entry added September 29, 2023. Read November 18, 2026.
  • FDA. Bulk drug substances nominated for use in compounding under section 503A, Category 3, list updated May 14, 2026.
  • FDA. Drugs@FDA record for Macrilen (macimorelin), NDA 205598, original approval December 20, 2017.
  • FDA. Import Alert 66-41, detention without physical examination of unapproved new drugs.
  • HHS. Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances, Federal Register, October 30, 2026, Appendix A.
  • World Anti-Doping Agency. 2026 Prohibited List, section S2.2.4, in force January 1, 2026.
  • ClinicalTrials.gov, searched for GHRP-6 and related terms on November 18, 2026: no registered GHRP-6 study. Related records: NCT00381602 (GHRP-1, terminated), NCT00846872 (GHRP-3, withdrawn).

This article is educational content from PeptIQ.io. It is not medical advice. Talk with a licensed clinician before starting, stopping, or changing any peptide, medication, or injection practice.

For clinics: running peptide or GLP-1 programs for patients? See PeptIQ.io for providers: protocol templates, a patient app, and adherence tracking in one console.

Share this article

Track Your Peptide Protocols

Use PeptIQ to log injections and vial supply, use peptiq.io calculators for math on the web, and keep protocols organized.

Stay ahead of the peptide conversation

Weekly-ish notes on new research, wiki trends, and practical tracking tips. No spam — unsubscribe anytime.

Educational updates only — not medical advice. Privacy